5-Amino-1MQ Benefits: What Studies Report

What 5-Amino-1MQ Is, and What the Available Literature Describes

5-Amino-1MQ (5-amino-1-methylquinolinium) is described in research contexts as a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosylmethionine onto nicotinamide. Because of that, almost all of the indexed literature relevant to its claimed effects is literature about NNMT — the enzyme target — rather than about any finished product. A 2021 review in Molecular Metabolism positioned NNMT at the intersection of cellular metabolism and epigenetic regulation, linking the enzyme to both NAD⁺-related metabolism and methyl-group availability (PMID 33453420). That framing is the reason NNMT inhibition has been studied across such different outcome domains: metabolism, cardiac function, limb perfusion, fibrosis and tumour immunology.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, and no finding below should be read as an expected outcome in a person. A broader background overview is kept separately on the 5-Amino-1MQ learn page.

One caveat applies to every section that follows. The studies cited here tested NNMT inhibition or examined NNMT biology; they are not interchangeable with testing a specific consumer compound in humans, and the paper titles and abstract scope cited below are the limit of what is stated on this page. Where a model is an animal or a cell system, that is labelled.

Evidence by Outcome Domain, at a Glance

Metabolic Outcomes: What Studies Report

The metabolic domain is the one most often attached to 5-Amino-1MQ in general discussion, and it is also where the citation set is thinnest in human terms. A 2024 paper in Diabetes, Obesity & Metabolism reported that nicotinamide N-methyltransferase inhibition mitigated obesity-related metabolic dysfunction (PMID 39161060). The title of that study describes an intervention against NNMT and a metabolic-dysfunction endpoint; it does not describe a randomised clinical trial in human participants, and this page does not state any dose, duration or magnitude of change because those details are outside what can be verified here.

The mechanistic rationale behind that work is set out in the 2021 Molecular Metabolism review, which described NNMT as sitting at the crossroads of cellular metabolism and epigenetic regulation (PMID 33453420). Reviews of this kind summarise a field; they do not establish that inhibiting the enzyme changes body weight or body composition in people, and researchers writing in this area have generally treated NNMT as a target under investigation rather than a settled one.

Cardiac Outcomes: What Studies Report

A 2025 study in Pharmacological Research reported that nicotinamide N-methyltransferase inhibition improved cardiac function and structure in a mouse model of heart failure with preserved ejection fraction (PMID 40484359). Two features of that study matter for interpretation. First, the model was a mouse model, so the findings describe rodent physiology under an induced disease state rather than human cardiac outcomes. Second, the endpoints were function and structure within that model — not symptoms, hospitalisation or survival in patients.

Heart-failure models are frequently used to screen metabolic targets, and a positive signal in one is a reason for further study rather than evidence of clinical benefit. The study reported a direction of effect in its model; it did not test the compound in people with heart failure (PMID 40484359).

Exercise and Limb Function: What Studies Report

Claims about stamina or exercise capacity often trace back to vascular and muscle work. In 2025, a paper in Physiological Reports reported that nicotinamide N-methyltransferase inhibition improved limb function in experimental peripheral artery disease (PMID 41108586). The word "experimental" in the title signals an induced animal model of impaired limb perfusion, not healthy human volunteers and not athletic performance testing.

Researchers studying peripheral artery disease typically measure functional capacity in an ischaemic limb — a very different question from whether a healthy person's training capacity changes. The reported improvement applies to the disease model that was studied (PMID 41108586), and extending it to general exercise performance would go beyond what the paper examined.

Fibrosis and Kidney Findings: What Studies Report

Two papers address fibrosis from different angles. A 2023 study in the International Journal of General Medicine examined nicotinamide N-methyl transferase as a predictive marker of tubular fibrosis in chronic kidney disease (PMID 37576910). That is a biomarker question — whether the enzyme tracks with a disease process — and not a test of whether inhibiting it changes kidney outcomes.

A 2026 paper in MedComm reported that NNMT epigenetically activated fibronectin 1 through H3K9me3 remodelling in clear cell renal cell carcinoma (PMID 42440812). This is molecular cancer biology describing how the enzyme influences gene regulation in tumour cells. It supports the broader mechanistic picture of NNMT as an epigenetic modifier, consistent with the review framing (PMID 33453420), but it says nothing about healthy-tissue outcomes.

Cancer and Immune Findings: What Studies Report

The largest cluster of recent NNMT literature is oncological, and it cuts in a direction that is often missing from benefit-oriented summaries. A 2025 study in Nature reported that NNMT inhibition in cancer-associated fibroblasts restored antitumour immunity (PMID 40702186). A 2024 study in the Journal for ImmunoTherapy of Cancer reported that NNMT in cancer-associated fibroblasts drove tumour progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (PMID 39067875).

Related work extended the pattern to other tumour types. Researchers reported that NNMT promoted drug resistance in lung cancer using nascent proteomic profiling (PMID 40679940), and a 2026 paper in Oncogene examined enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signalling in the tumour microenvironment (PMID 42310095).

Taken together, this body of work treats NNMT as a drug target in oncology rather than as a wellness lever: the reported value of inhibition in those papers was in tumour or immune contexts (PMID 40702186, PMID 42310095). None of those studies evaluated the enzyme's inhibition in healthy individuals, and none reported outcomes relevant to everyday use.

Claimed Benefits This Citation Set Does Not Support

Several outcomes commonly attached to 5-Amino-1MQ are simply not addressed by the papers available here. Stated plainly:

• Weight loss or fat loss in humans. The metabolic paper cited above described mitigation of obesity-related metabolic dysfunction under NNMT inhibition (PMID 39161060); it is not a human weight-loss trial, and no human weight outcome appears in this set.
• Muscle growth or strength gains. No paper cited here measured hypertrophy or strength. The closest functional endpoint was limb function in an experimental peripheral artery disease model (PMID 41108586).
• Longevity or anti-ageing effects. Lifespan was not an endpoint in any cited study; NAD⁺-related mechanism was discussed at review level only (PMID 33453420).
• Energy, cognition, skin or hair outcomes. Absent entirely from this citation set.
• Human dosing information. No dose, schedule or duration is stated anywhere on this page because none can be sourced from the verified papers listed below.

Adverse Events and Tolerability: What Studies Report

None of the papers cited on this page were designed as human safety or tolerability studies, and no adverse-event rates, toxicity thresholds or withdrawal figures are reported here because the citation set does not contain them. The work available is preclinical and mechanistic: a mouse cardiac model (PMID 40484359), an experimental limb-ischaemia model (PMID 41108586), and tumour-biology investigations (PMID 40702186, PMID 39067875).

A second point follows from the oncology literature. Because NNMT is deeply involved in tumour-microenvironment signalling and drug resistance (PMID 40679940) and in epigenetic regulation of gene expression (PMID 42440812), modulating the enzyme is a systemic intervention with effects across tissues rather than a narrowly metabolic one. Reviewers have made the same general observation about NNMT's dual metabolic and epigenetic roles (PMID 33453420). The absence of human safety data in this set is a gap, not a reassurance.

Regulatory Status and How Far These Findings Travel

5-Amino-1MQ is not an approved medicine for any indication in the United States or the European Union; material supplied for laboratory work is typically labelled research-use-only, which is a laboratory designation and not an assertion of human safety. That status is consistent with the stage of the literature: target-level and preclinical, with no human efficacy trial of the compound appearing in the papers cited here.

When reading any summary of 5-Amino-1MQ, three questions separate a reported finding from an implied promise. What species or system was studied — mouse, cell line, human tissue? What exactly was measured — cardiac structure (PMID 40484359), limb function (PMID 41108586), tumour immunity (PMID 40702186)? And was the intervention the specific compound, or inhibition of the enzyme by some means? Where those answers are vague, the claim is usually travelling further than the data.

References

• NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity (Nature, 2025)
• NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (Journal for ImmunoTherapy of Cancer, 2024)
• Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model (Pharmacological Research, 2025)
• Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (Diabetes, Obesity & Metabolism, 2024)
• Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease (Physiological Reports, 2025)
• Nicotinamide N-methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling (Molecular Oncology, 2026)
• Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation (Molecular Metabolism, 2021)
• Nicotinamide N-Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD (International Journal of General Medicine, 2023)
• Nicotinamide N-Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma (MedComm, 2026)
• Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment (Oncogene, 2026)